X-group (possible homology)

211 Glyoxalase/Bleomycin resistance protein/Dihydroxybiphenyl dioxygenase

Open in classification tree →

Ligands and drugs

4,345

Member domains

1,968

with ligand contacts (≤ 4 Å)

45.3% of members

1,501

with DrugDomain annotations

34.5% of members

607

with a DrugBank compound

14.0% of members

Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.

Chemical profile

ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.

Proteins with classified ligands

Superclasses bound (of 23)

8.9

Superclasses per 20 proteins

broader than 75% of the 256 X-groups with enough proteins to compare (median 7.6)

The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.

Superclass	Proteins	Expected	Ratio	Significance
Benzenoids	17	6.5	2.62×	q = 6.1e-4
Organic acids and derivatives	28	13.7	2.04×	q = 4.9e-4
Homogeneous metal compounds	75	43.6	1.72×	q < 0.0001
Organoheterocyclic compounds	15	13.7	1.10×	q = 0.73
Homogeneous non-metal compounds	15	19.1	0.79×	q = 0.44
Organic oxygen compounds	11	17.7	0.62×	q = 0.13
Lipids and lipid-like molecules	4	9.9	0.41×	q = 0.07
Nucleosides, nucleotides, and analogues	1	24.5	0.04×	q < 0.0001
Organic 1,3-dipolar compounds	1	0.1	13×	not tested
Organosulfur compounds	3	1.8	1.64×	not tested
Phenylpropanoids and polyketides	2	1.9	1.08×	not tested
Mixed metal/non-metal compounds	2	1.9	1.07×	not tested
Organic nitrogen compounds	3	2.8	1.06×	not tested

enriched (q < 0.05)depleted (q < 0.05)not significantnot tested (expected < 5)

Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.

DrugBank compounds

DrugBank	PDB ligand	Name	Domains
DB00828	FCN	Fosfomycin	38
DB00290	BLM	Bleomycin	36
DB01702	DHY	2-(3,4-Dihydroxyphenyl)Acetic Acid	30
DB03407	4NC	4-Nitrocatechol	30
DB08307	NTD	2-{HYDROXY[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]METHYLENE}CYCLOHEXANE-1,3-DIONE	26
DB02923	BPY	Biphenyl-2,3-Diol	14
DB03345	BME	Mercaptoethanol	13
DB01235	DAH	Levodopa	12
DB00143	GSH	Glutathione	10
DB04120	MCT	4-Methyl-1,2-Benzenediol	10
DB00151	CYS	Cysteine	8
DB00529	PPF	Foscarnet	8
DB03130	GNB	S-P-Nitrobenzyloxycarbonylglutathione	8
DB03309	NHE	N-cyclohexyltaurine	8
DB03434	MPO	3-(N-morpholino)propanesulfonic acid	8
DB03602	GSB	S-benzylglutathione	8
DB03900	TBU	tert-butanol	8
DB07914	HPX	2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid	8
DB11091	PEO	Hydrogen peroxide	8
DB02850	869	DAS869	7

Most frequently bound compounds

PDB ligand	Name	Domains in contact
COmetal	COBALT (II) ION	365
MNmetal	MANGANESE (II) ION	337
FE2metal	FE (II) ION	318
P6G	HEXAETHYLENE GLYCOL	297
ZNmetal	ZINC ION	231
CL	CHLORIDE ION	148
FEmetal	FE (III) ION	146
NImetal	NICKEL (II) ION	67
CAmetal	CALCIUM ION	48
FCN	FOSFOMYCIN	43
BLM	BLEOMYCIN A2	40
MGmetal	MAGNESIUM ION	39
4NC	4-NITROCATECHOL	30
DHY	2-(3,4-DIHYDROXYPHENYL)ACETIC ACID	30
92X	1,5-dimethyl-3-(2-methylphenyl)-6-(2-oxidanyl-6-oxidanylidene-cyclohexen-1-yl)carbonyl-quinazoline-2,4-dione	28
NTD	2-{HYDROXY[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]METHYLENE}CYCLOHEXANE-1,3-DIONE	27
94L	3-(2,6-dimethylphenyl)-1-methyl-6-(2-oxidanyl-6-oxidanylidene-cyclohexen-1-yl)carbonyl-quinazoline-2,4-dione	24
A81	6,6'-(4-nitro-1H-pyrazole-3,5-diyl)bis(3-bromopyrazolo[1,5-a]pyrimidin-2(1H)-one)	20
NAG	2-acetamido-2-deoxy-beta-D-glucopyranose	18
BME	BETA-MERCAPTOETHANOL	17